Stempeutics gets DCGI nod for Phase 3 clinical trial on its product for treating COVID patients

Stempeucel exhibits potent immuno-modulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the body's immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs, Stempeutics said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3nwT2nK
via IFTTT